S16 Association of Quality of Life With Clinical Remission, HEMR, and Bowel Urgency in Patients With Ulcerative Colitis Treated With Mirikizumab

, respectively. In these 2 patients, CRP and ESR, which are laboratory biomarkers of in ﬂ ammation, decreased by an average of 86% from labs drawn prior to UPA initiation. Conclusions: Patients selected for treatment with o ﬀ label UPA for Crohn ’ s disease had a history of long disease duration with multiple biologic failures and severe disease activity. Improvements in in ﬂ ammatory markers were seen in this refractory patient population with initiation of UPA. UPA has already been approved for treatment of UC and appears to be a promising new option for those with CD refractory to existing therapies. As time passes, more data will be collected to support UPA as an e ﬀ ective treatment for refractory CD.